盘前跌近5%!诺和诺德“减肥神药”进入美国医保价格谈判

华尔街见闻
17 Jan

美国政府周五表示,诺和诺德减肥药Wegovy和糖尿病药物Ozempic等15种药物被列入美国政府计划于2027年进行的医保价格谈判中。这一举措源于拜登政府于2022年签署的《通货膨胀削减法案》,旨在降低 Medicare(医疗保险)对高价药物的支出。 在这15种药物中,还包括辉瑞(Pfizer)的癌症药物Ibrance和Xtandi,葛兰素史克(GSK)的哮喘和慢性阻塞性肺病治疗药Trelegy ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10